Gene Expression Profile of Human Colon Cancer Cells Treated with Cross-Reacting Material 197,a Diphtheria Toxin Non-Toxic Mutant

Abstract

Cross-Reacting Material 197 (CRM197) is a diphtheria toxin non-toxic mutant that has shown antitumor activity in mice and humans. It is still unclear whether this anti-tumorigenic effect depends on its strong inflammatory-immunological property, its ability to inhibit heparin-binding epidermal growth factor (HB-EGF), or even its possible weak toxicity. CRM197 is utilized as a specific inhibitor of HB-EGF that competes for the epidermal growth factor receptor (EGFR), overexpressed in colorectal cancer and implicated in its progression. In this study we evaluate the effects of CRM197 on HT-29 human colon cancer cell line behaviour and, for CRM197 recognized ability to inhibit HB-EGF, its possible influence on EGFR activation. In particular, while HT-29 does not show any reduction of viability after CRM197 treatment (MTT modified assay), or changes in cell cycle distribution (flow cytometry), in EGFR localization, phospho-EGFR detected signals (immunohistochemistry) or in morphology (scanning electron microscopy, SEM) they show a change in the gene expression profile by microarray analysis (cDNA microarray SS-H19k8). The overexpression of genes like protein phosphatase 2, catalytic subunit, alpha isozyme (PPP2CA), guanine nucleotide-binding protein G subunit alpha-1(GNAIl) and butyrophilin, subfamily 2, member A1 (BTN2A1) has been confirmed with real-time-qPCR. This is the first study where the CRM197 treatment on HT-29 shows a possible scarce implication of endogenous HB-EGF on EGFR expression and cancer cell development. At the same time, our results show the alteration of a specific and selected number of genes.

Keywords

CRM197 colon cancer microarray

References

Buzzi

Maistrello

. Inhibition of growth of Erlich tumors in Swiss mice by diphtheria toxin. Cancer Res 1973; 33:2349–53.

Buzzi

. Diphtheria toxin treatment of human advanced cancer. Cancer Res 1982; 42:2054–8.

Buzzi

Rubboli

Buzzi

Morisi

Pironi

. CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunol Immunother 2004; 53:1041–8.

Giannini

Rappuoli

Ratti

. The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Res 1984; 12:4063–9.

Mitamura

Higashiyama

Taniguchi

Klagsbrun

Mekada

. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem 1995; 270:1015–9.

Higashiyama

Abraham

Miller

Fiddes

Klagsbrun

. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF Science 1991; 251:936–9.

Miyamoto

Yagi

Yotsumoto

Kawarabayashi

Mekada

. Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Sci 2006; 97:341–7.

Kageyama

Ohishi

Miyamoto

Mizushima

Iwamoto

Mekada

. Diphtheria toxin mutant CRM197 possesses weak EF2-ADP-ribosyl activity that potentiates its anti-tumorigenic activity. J Biochem 2007; 142:95–104.

Hashimoto

Higashiyama

Asada

. Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. J Biol Chem 1994; 269:20060–6.

10.

Freeman

Yoo

Raab

Soker

Adam

Schneck

Renshaw

Klagsbrun

Atala

. Heparin-binding EGF-like growth factor is an autocrine growth factor for human urothelial cells and is synthesized by epithelial and smooth muscle cells in the human bladder. J Clin Invest 1997; 99: 1028–36.

11.

Raab

Klagsbrun

. Heparin-binding EGF-like growth factor. Biochim Biophys Acta 1997; 1333: 179–99.

12.

Qiao

Ghani

Caruso

. Diphtheria toxin mutant CRM197 is an inhibitor of protein synthesis that induces cellular toxicity. Toxicon 2008; 51:473–7.

13.

Kimura

Saito

Kimata

Kohno

. Transgenic mice expressing a fully nontoxic diphtheria toxin mutant, not CRM197 mutant, acquire immune tolerance against diphtheria toxin. J Biochem 2007; 142:105–12.

14.

Ichise

Adachi

Ohishi

Ikawa

Okabe

Iwamoto

Mekada

. Humanized gene replacement in mice reveals the contribution of cancer stroma-derived HB-EGF to tumor growth. Cell Struct Funct 2010; 35:3–13.

15.

Yotsumoto

Yagi

Suzuki

. Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun 2008; 365:555–61.

16.

Solmi

Lauriola

Francesconi

. Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines. BMC Cancer 2008; 8:227.

17.

Yonezawa

Wada

Tatsuguchi

. Heregulin-induced VEGF expression via the ErbB3 signaling pathway in colon cancer. Digestion 2009; 80:215–25.

18.

Mosmann

Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55–63.

19.

Freshney

. Culture of animal cells: a manual of basic technique. In Technique. Fogh

, ed. Plenum Press

NY and London. New York

1987.

20.

Nusse

Beisker

Hoffmann

Tarnok

. Flow cytometric analysis of G1 - and G2/M-phase subpopulations in mammalian cell nuclei using side scatter and DNA content measurements. Cytometry 1990; 11:813–21.

21.

Livak

Schmittgen

. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402–8.

22.

Eisen

Spellman

Brown

Botstein

. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95:14863–8.

23.

Pan

Sengoku

Goishi

Takuma

Yamashita

Wada

Ishikawa

. The soluble and membrane-anchored forms of heparin-binding epidermal growth factor-like growth factor appear to play opposing roles in the survival and apoptosis of human luteinized granulosa cells. Mol Hum Reprod 2002; 8:734–41.

24.

Yagi

Yotsumoto

Sonoda

Kuroki

Mekada

Miyamoto

. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer. Int J Cancer 2009; 124:1429–39.

25.

Bauer-Mehren

Furlong

Sanz

. Pathway databases and tools for their exploitation: benefits, current limitations and challenges. Mol Syst Biol 2009; 5:290.

26.

Rowinsky

. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 2004; 55:433–57.

27.

Antignani

Youle

. Endosome fusion induced by diphtheria toxin translocation domain. Proc Natl Acad Sci USA 2008; 105:8020–5.

28.

Guichard

Pedruzzi

Fay

. Dihydroxyphenylethanol induces apoptosis by activating serine/threonine protein phosphatase PP2A and promotes the endoplasmic reticulum stress response in human colon carcinoma cells. Carcinogenesis 2006; 27:1812–27.

29.

Packman

Weldon

Hamlett

Rhodes

. Protein phosphatase 2A, a negative regulator of the ERK signaling pathway, is activated by tyrosine phosphorylation of putative HLA class II-associated protein I (PHAPI)/pp32 in response to the antiproliferative lectin, jacalin. J Biol Chem 2004; 279:41377–83.

30.

Suki

Abramowitz

Mattera

Codina

Birnbaumer

. The human genome encodes at least three non-allellic G proteins with alpha i-type subunits. FEBS Lett 1987; 220:187–92.

31.

Jeong

Rao

Ogg

Hathout

Fenselau

Mather

. The PRY/SPRY/B30.2 domain of butyrophilin 1A1 (BTN1A1) binds to xanthine oxidoreductase: implications for the function of BTN1A1 in the mammary gland and other tissues. J Biol Chem 2009; 284:22444–56.

32.

Clarke

Dickson

Harris

Grabowska

Watson

. Gastrin enhances the angiogenic potential of endothelial cells via modulation of heparin-binding epidermal-like growth factor. Cancer Res 2006; 66:3504–12.